IL140249A0 - Muscarinic antagonists - Google Patents
Muscarinic antagonistsInfo
- Publication number
- IL140249A0 IL140249A0 IL14024999A IL14024999A IL140249A0 IL 140249 A0 IL140249 A0 IL 140249A0 IL 14024999 A IL14024999 A IL 14024999A IL 14024999 A IL14024999 A IL 14024999A IL 140249 A0 IL140249 A0 IL 140249A0
- Authority
- IL
- Israel
- Prior art keywords
- muscarinic antagonists
- muscarinic
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10798398A | 1998-06-30 | 1998-06-30 | |
| PCT/US1999/012821 WO2000000488A1 (en) | 1998-06-30 | 1999-06-28 | Muscarinic antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL140249A0 true IL140249A0 (en) | 2002-02-10 |
Family
ID=22319562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14024999A IL140249A0 (en) | 1998-06-30 | 1999-06-28 | Muscarinic antagonists |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1091956B1 (xx) |
| JP (1) | JP3344997B2 (xx) |
| KR (1) | KR20010053254A (xx) |
| CN (1) | CN1146559C (xx) |
| AR (1) | AR019167A1 (xx) |
| AT (1) | ATE272632T1 (xx) |
| AU (1) | AU756484B2 (xx) |
| CA (1) | CA2336000C (xx) |
| DE (1) | DE69919171T2 (xx) |
| ES (1) | ES2221399T3 (xx) |
| HU (1) | HUP0104058A2 (xx) |
| IL (1) | IL140249A0 (xx) |
| MY (1) | MY133108A (xx) |
| NZ (1) | NZ508910A (xx) |
| TW (1) | TW474933B (xx) |
| WO (1) | WO2000000488A1 (xx) |
| ZA (1) | ZA200007555B (xx) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| DE60021370C5 (de) * | 1999-05-04 | 2007-11-08 | Schering Corp. | Piperazinderivate verwendbar als ccr5 antagonisten |
| US6689765B2 (en) | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| US6635646B1 (en) | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
| US6294554B1 (en) | 1999-09-22 | 2001-09-25 | Schering Corporation | Muscarinic antagonists |
| ES2215055T3 (es) * | 1999-09-22 | 2004-10-01 | Schering Corporation | Antagonistas muscarinicos. |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| CN1298715C (zh) * | 2001-03-13 | 2007-02-07 | 先灵公司 | 作为组胺h3拮抗剂的非咪唑化合物 |
| DE60209736T2 (de) | 2001-07-02 | 2006-11-02 | Astrazeneca Ab | Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| US20080200505A1 (en) * | 2005-05-27 | 2008-08-21 | Astrazeneca Ab | Piperidines for the Treatment of Chemokine Mediated Diseases |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| EP2402316A1 (en) | 2005-07-21 | 2012-01-04 | AstraZeneca AB (Publ) | Piperidine derivatives |
| AU2008225766B2 (en) | 2007-03-15 | 2012-06-07 | Novartis Ag | Organic compounds and their uses |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| CN104356056B (zh) * | 2014-11-19 | 2017-04-05 | 南京华威医药科技开发有限公司 | 吡仑帕奈中间体的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
-
1999
- 1999-06-28 ES ES99931768T patent/ES2221399T3/es not_active Expired - Lifetime
- 1999-06-28 NZ NZ508910A patent/NZ508910A/xx unknown
- 1999-06-28 CN CNB998100765A patent/CN1146559C/zh not_active Expired - Fee Related
- 1999-06-28 CA CA002336000A patent/CA2336000C/en not_active Expired - Fee Related
- 1999-06-28 TW TW088110871A patent/TW474933B/zh not_active IP Right Cessation
- 1999-06-28 IL IL14024999A patent/IL140249A0/xx unknown
- 1999-06-28 MY MYPI99002663A patent/MY133108A/en unknown
- 1999-06-28 AT AT99931768T patent/ATE272632T1/de not_active IP Right Cessation
- 1999-06-28 WO PCT/US1999/012821 patent/WO2000000488A1/en active IP Right Grant
- 1999-06-28 KR KR1020007014935A patent/KR20010053254A/ko not_active Application Discontinuation
- 1999-06-28 DE DE69919171T patent/DE69919171T2/de not_active Expired - Lifetime
- 1999-06-28 JP JP2000557249A patent/JP3344997B2/ja not_active Expired - Fee Related
- 1999-06-28 EP EP99931768A patent/EP1091956B1/en not_active Expired - Lifetime
- 1999-06-28 HU HU0104058A patent/HUP0104058A2/hu unknown
- 1999-06-28 AR ARP990103104A patent/AR019167A1/es unknown
- 1999-06-28 AU AU48201/99A patent/AU756484B2/en not_active Ceased
-
2000
- 2000-12-15 ZA ZA200007555A patent/ZA200007555B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1091956A1 (en) | 2001-04-18 |
| EP1091956B1 (en) | 2004-08-04 |
| CA2336000A1 (en) | 2000-01-06 |
| DE69919171D1 (de) | 2004-09-09 |
| HUP0104058A2 (hu) | 2002-03-28 |
| JP2002519349A (ja) | 2002-07-02 |
| AU4820199A (en) | 2000-01-17 |
| CN1146559C (zh) | 2004-04-21 |
| NZ508910A (en) | 2003-01-31 |
| ZA200007555B (en) | 2002-03-15 |
| WO2000000488A1 (en) | 2000-01-06 |
| KR20010053254A (ko) | 2001-06-25 |
| TW474933B (en) | 2002-02-01 |
| AR019167A1 (es) | 2001-12-26 |
| CA2336000C (en) | 2006-10-10 |
| AU756484B2 (en) | 2003-01-16 |
| DE69919171T2 (de) | 2005-08-04 |
| MY133108A (en) | 2007-10-31 |
| CN1314905A (zh) | 2001-09-26 |
| JP3344997B2 (ja) | 2002-11-18 |
| ATE272632T1 (de) | 2004-08-15 |
| ES2221399T3 (es) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1018776A1 (en) | Muscarinic antagonists | |
| IL143226A0 (en) | Pyrrolidine derivatives-ccr-3 receptor antagonists | |
| HK1054391A1 (zh) | 毒蕈碱拮抗劑 | |
| IL140249A0 (en) | Muscarinic antagonists | |
| SG80041A1 (en) | Muscarinic receptor antagonists | |
| IL141050A0 (en) | Muscarinic agonists and antagonists | |
| HUP0101753A3 (en) | Boring-tool | |
| IL137329A0 (en) | Vla-4 antagonists | |
| HK1043590A1 (zh) | 毒蕈碱性拮抗物 | |
| GB9816729D0 (en) | Substituted cyclohexylaminopyrimidines | |
| HK1039937A1 (zh) | 取代的3-硫代氨基甲酰基吡唑類化合物 | |
| GB9818418D0 (en) | Sub | |
| AU137693S (en) | Sawhorse | |
| PL347397A1 (en) | Substituted 3-aryl-pyrazoles | |
| AU5112699A (en) | 5-HT1f antagonists | |
| HUP0102476A3 (en) | Substituted cyclooctadepsipeptides | |
| HK1039335A1 (zh) | 取代的苯甲酰基環已二酮類化合物 | |
| ZA200003475B (en) | Muscarinic receptor antagonists. | |
| TW445937U (en) | Combination tool set | |
| GB9801933D0 (en) | Combination square | |
| GB9811283D0 (en) | Vironectin receptor antagonists | |
| ZA961293B (en) | Muscarinic antagonists | |
| GB9801657D0 (en) | Worktable construction | |
| PL341899A1 (en) | Vla-4 antagonists | |
| AU135297S (en) | Top |